| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-05 Alectinib | Pharmaceutical products | - | Jul 30, 2028 | Jul 1, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-08 Framework | Pharmaceutical products | - | Jul 30, 2028 | Jul 1, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 26 - Tralokinumab | Pharmaceutical products | - | Jul 30, 2028 | Jun 17, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-10 | Pharmaceutical products | - | Jul 30, 2028 | Jun 15, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-12 | Pharmaceutical products | - | Jun 29, 2028 | Jun 14, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-22 - Ustekinumab | Pharmaceutical products | - | Jul 30, 2027 | Jun 7, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-21 - Golimumab | Pharmaceutical products | - | Jul 30, 2027 | Jun 7, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-32 - Golimumab | Pharmaceutical products | - | Jul 30, 2026 | Jun 7, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-25 - Follitropin alfa | Pharmaceutical products | - | Jul 30, 2028 | Jun 7, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-23 - Darbepoetin alfa | Pharmaceutical products | - | Jul 30, 2028 | Jun 4, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-09 - Teduglutid | Pharmaceutical products | - | Jun 29, 2028 | Jun 1, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 20 - Peginterferon beta 1a | Pharmaceutical products | - | Jul 30, 2028 | May 31, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-31 - Denosumab | Pharmaceutical products | - | Nov 29, 2027 | May 25, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 19 - Denosumab (Wirkstärke 60mg) | Pharmaceutical products | - | Nov 29, 2027 | May 25, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-04 Cariprazin | Pharmaceutical products | - | Jun 30, 2028 | May 20, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 18 Omalizumab | Pharmaceutical products | - | Jun 30, 2028 | May 20, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab | Pharmaceutical products | - | Oct 30, 2027 | May 20, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 14 - Lipegfilgrastim | Pharmaceutical products | - | Jun 29, 2028 | May 19, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 17 Interferon beta-1b (Fertigarzneimittel: Betaferon(R)) | Pharmaceutical products | - | Jun 30, 2028 | May 19, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 15 Ranibizumab | Pharmaceutical products | - | Jun 30, 2027 | May 18, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 16 Epoetin theta | Pharmaceutical products | - | Jun 30, 2028 | May 18, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-08 | Pharmaceutical products | - | Jun 29, 2028 | May 7, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-13 - Romiplostim | Pharmaceutical products | - | Jun 29, 2028 | May 7, 2026 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 12 Epoetin alfa und Epoetin zeta | Pharmaceutical products | - | Jun 30, 2028 | May 7, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-30 - Lenograstim | Pharmaceutical products | - | Dec 30, 2027 | Apr 23, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-03 - Dolutegravir/Rilpivirin (Wirkstoffkombination) | Pharmaceutical products | - | May 31, 2028 | Apr 23, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-11 - Infliximab (Darreichungsform zur intravenösen Anwendung) | Pharmaceutical products | - | May 30, 2028 | Apr 19, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-10 - Infliximab (Darreichungsform zur subkutanen Injektion) | Pharmaceutical products | - | May 30, 2028 | Apr 19, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-07 | Pharmaceutical products | - | May 30, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-06 - Safinamid | Pharmaceutical products | - | Apr 29, 2027 | Mar 26, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-09 - Etanercept | Pharmaceutical products | - | Apr 29, 2028 | Mar 22, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-08 - Filgrastim | Pharmaceutical products | - | Apr 30, 2028 | Mar 18, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-04 - Natalizumab i.v. | Pharmaceutical products | - | Apr 29, 2028 | Mar 18, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-07 - Tocilizumab | Pharmaceutical products | - | Apr 30, 2028 | Mar 18, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-05 - Pegfilgrastim | Pharmaceutical products | - | Apr 29, 2028 | Mar 18, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-05 | Pharmaceutical products | - | Apr 29, 2028 | Mar 17, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-06 - Teriparatid | Pharmaceutical products | - | Apr 29, 2028 | Mar 15, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-02 - Ponatinib | Pharmaceutical products | - | Apr 29, 2028 | Mar 15, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-06 | Pharmaceutical products | - | Mar 30, 2028 | Mar 5, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-04 - Tramadol/Dexketoprofen | Pharmaceutical products | - | Mar 30, 2028 | Mar 2, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-03b - Eculizumab (inkl. der Indikation gMG und NMOSD) | Pharmaceutical products | - | Aug 30, 2027 | Feb 24, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD) | Pharmaceutical products | - | Aug 30, 2027 | Feb 24, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-03 | Pharmaceutical products | - | Mar 30, 2028 | Feb 17, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-01 - Cannabis | Pharmaceutical products | - | Mar 30, 2028 | Feb 16, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-10 | Pharmaceutical products | - | Sep 29, 2027 | Feb 16, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-02 - Interferon beta 1a (Fertigarzneimittel: Rebif (R)) | Pharmaceutical products | - | Mar 30, 2028 | Feb 9, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-01 - Abaloparatid | Pharmaceutical products | - | Feb 28, 2028 | Jan 27, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-02 - Lanreotid | Pharmaceutical products | - | Feb 28, 2028 | Jan 21, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-01 | Pharmaceutical products | - | Feb 28, 2028 | Jan 18, 2026 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-16 | Pharmaceutical products | - | Jan 30, 2028 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-08 | Pharmaceutical products | - | Aug 30, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-38 - PEG-Epoetin beta | Pharmaceutical products | - | Jan 30, 2028 | Dec 3, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-39 - Epoetin beta | Pharmaceutical products | - | Jan 30, 2028 | Dec 3, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-37 - Peginterferon alfa-2a | Pharmaceutical products | - | Jan 30, 2028 | Nov 23, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-36 - Natalizumab (Darreichungsform zur subkutanen Injektion) | Pharmaceutical products | - | Jan 30, 2028 | Nov 23, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-15 | Pharmaceutical products | - | Dec 30, 2027 | Nov 17, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-35 - Baricitinib | Pharmaceutical products | - | Dec 30, 2027 | Nov 13, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-34 - Formoterol/Glycopyrronium/Budesonid (Wirkstoffkombination) | Pharmaceutical products | - | Nov 29, 2027 | Oct 27, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-13 | Pharmaceutical products | - | Dec 30, 2027 | Oct 22, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-33 - Propranolol (Darreichungsform: Lösung zum Einnehmen) | Pharmaceutical products | - | Dec 30, 2027 | Oct 19, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-28 - Abatacept | Pharmaceutical products | - | Nov 29, 2027 | Oct 14, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-32 - Doravirin/Lamivudin/Tenofovir (Wirkstoffkombination) | Pharmaceutical products | - | Nov 29, 2027 | Oct 12, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-31 - Doravirin | Pharmaceutical products | - | Nov 29, 2027 | Oct 12, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-14 - Guanfacin (RET, Wirkstärken: 1-4 mg) | Pharmaceutical products | - | Oct 30, 2026 | Oct 8, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-30 - Afatinib | Pharmaceutical products | - | Oct 30, 2027 | Sep 24, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-29 - Isavuconazol | Pharmaceutical products | - | Oct 30, 2027 | Sep 22, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-12 | Pharmaceutical products | - | Oct 30, 2027 | Sep 18, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-27 - Ribociclib | Pharmaceutical products | - | Oct 30, 2027 | Sep 17, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-28 - Abemaciclib | Pharmaceutical products | - | Oct 30, 2027 | Sep 17, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-27 - Tocilizumab | Pharmaceutical products | - | Oct 30, 2026 | Sep 14, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-26 - Insulin lispro (ATC: A10AB04, Wirkstärke: 100 U/ml) | Pharmaceutical products | - | Oct 30, 2027 | Sep 9, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-26 - Ponesimod | Pharmaceutical products | - | Oct 30, 2027 | Sep 8, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-11 - Eltrombopag | Pharmaceutical products | - | Sep 29, 2027 | Aug 25, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-25 - Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid (Wirkstoffkombination) | Pharmaceutical products | - | Oct 30, 2027 | Aug 21, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-22 - Aclidiniumbromid | Pharmaceutical products | - | Sep 29, 2027 | Aug 18, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-24 - Vericiguat | Pharmaceutical products | - | Sep 29, 2027 | Aug 18, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-22 - Triptorelin embonat | Pharmaceutical products | - | Sep 29, 2027 | Aug 7, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-09 | Pharmaceutical products | - | Aug 30, 2027 | Jul 27, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-23 - Rilpivirin (Darreichungsform: Filmtabletten) | Pharmaceutical products | - | Sep 29, 2027 | Jul 22, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-21 - Sofosbuvir, Velpatasvir, Voxilaprevir (Wirkstoffkombination) | Pharmaceutical products | - | Aug 30, 2027 | Jul 22, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-20 - Pegfilgrastim | Pharmaceutical products | - | Aug 30, 2027 | Jul 16, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid | Pharmaceutical products | - | Aug 30, 2027 | Jul 13, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-09 Framework | Pharmaceutical products | - | Aug 30, 2026 | Jun 23, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-19 - Adalimumab | Pharmaceutical products | - | Jul 30, 2027 | Jun 12, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-18 - Insulin glargin (Wirkstärke: 100 U/ml) | Pharmaceutical products | - | Aug 30, 2027 | Jun 9, 2025 | Active |
| Germany – Batteries – Rahmenvertrag Einwegbatterien für Sprachprozessoren von Cochlea-Implantaten | Batteries | - | Dec 31, 2099 | Jun 3, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-16 - Agalsidase alfa | Pharmaceutical products | - | Jun 29, 2027 | May 25, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-17 -Agalsidase beta | Pharmaceutical products | - | Jun 29, 2027 | May 25, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-16 - Empagliflozin | Pharmaceutical products | - | Jun 29, 2027 | May 22, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-17 - Beclometason, Formoterol, Glycopyrronium (Wirkstoffkombination) ATC: R03AL09 | Pharmaceutical products | - | Jun 29, 2027 | May 22, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-14 | Pharmaceutical products | - | Jan 30, 2027 | May 21, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-20 - Metformin/Dapagliflozin (Wirkstoffkombination) | Pharmaceutical products | - | Jul 30, 2027 | May 19, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-15 | Pharmaceutical products | - | Jul 30, 2027 | May 19, 2025 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-13 - Insulin-isophan/Insulin, normal (human) (Wirkstoffkombination) | Pharmaceutical products | - | Jul 30, 2027 | May 11, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-18 - Glycopyrroniumbromid/Formoterol (Wirkstoffkombination) | Pharmaceutical products | - | Jul 30, 2027 | May 11, 2025 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-11 - Insulin, normal (human) | Pharmaceutical products | - | Jul 30, 2027 | May 11, 2025 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-12 - Insulin-isophan (human) | Pharmaceutical products | - | Jul 30, 2027 | May 11, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-19 - Tafamidis | Pharmaceutical products | - | May 30, 2027 | May 4, 2025 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-10 - Choriongonadotropin alfa | Pharmaceutical products | - | May 30, 2027 | Apr 22, 2025 | Active |
| Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-09 - Lutropin alfa / Follitropin alfa (Wirkstoffkombination) | Pharmaceutical products | - | May 30, 2027 | Apr 22, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-15 - Tacrolimus (Retardtabletten) | Pharmaceutical products | - | May 30, 2027 | Apr 21, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-13 - Fluticason, Umeclidinium, Vilanterol (Wirkstoffkombination) | Pharmaceutical products | - | May 30, 2027 | Apr 16, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-14 - Tiotropiumbromid/Olodaterol (Wirkstoffkombination) | Pharmaceutical products | - | May 30, 2027 | Apr 16, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-06 - Pegvisomant | Pharmaceutical products | - | May 30, 2027 | Apr 8, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-13 - Somatropin | Pharmaceutical products | - | Dec 30, 2026 | Apr 1, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-11 - Umeclidiniumbromid | Pharmaceutical products | - | Apr 29, 2027 | Mar 30, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-10 - Umeclidiniumbromid+Vilanterol | Pharmaceutical products | - | Apr 29, 2027 | Mar 27, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-04 - Follitropin beta | Pharmaceutical products | - | Apr 30, 2027 | Mar 16, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-03 - Interferon beta-1a (Fertigarzneimittelbezeichnung: Avonex(R)) | Pharmaceutical products | - | Apr 29, 2027 | Mar 16, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2025-09 - Cannabis | Pharmaceutical products | - | Mar 30, 2027 | Feb 24, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-02 - Rituximab (Darreichungsform zur subkutanen Injektion) | Pharmaceutical products | - | Feb 27, 2027 | Jan 23, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-07 - Lamivudin/Abacavir/Dolutegravir (Wirkstoffkombination) | Pharmaceutical products | - | Feb 27, 2027 | Jan 20, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-06 - Dolutegravir | Pharmaceutical products | - | Feb 27, 2027 | Jan 20, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-03 - Cobicistat/Elvitegravir/Emtricitabin/Tenofovirdisoproxil (Stribild(R)) | Pharmaceutical products | - | Feb 27, 2027 | Jan 20, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R)) | Pharmaceutical products | - | Feb 27, 2027 | Jan 20, 2025 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-01 | Pharmaceutical products | - | Feb 27, 2027 | Jan 20, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-05 - Emtricitabin/Tenofovirdisoproxil/Rilpivirin (Wirkstoffkombination) | Pharmaceutical products | - | Feb 27, 2027 | Jan 20, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-04 - Emtricitabin/Tenofoviralafenamid/Rilpivirin (Odefsey(R)) | Pharmaceutical products | - | Feb 27, 2027 | Jan 20, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R)) | Pharmaceutical products | - | Feb 27, 2027 | Jan 19, 2025 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-13 - Apremilast | Pharmaceutical products | - | Dec 29, 2026 | Nov 19, 2024 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-12 - Tofacitinib | Pharmaceutical products | - | Dec 29, 2026 | Nov 17, 2024 | Active |
| Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2024-14 - Bimatoprost / Timolol (Darreichungsform: Augentropfen als Einzeldosispipetten) | Pharmaceutical products | - | Dec 29, 2026 | Nov 17, 2024 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-12 - Dornase alfa | Pharmaceutical products | - | Dec 29, 2026 | Nov 17, 2024 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-13 | Pharmaceutical products | - | Dec 29, 2026 | Nov 14, 2024 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-10 - Pertuzumab / Trastuzumab (Wirkstoffkombination) | Pharmaceutical products | - | Dec 29, 2026 | Nov 13, 2024 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-10 - Tiotropiumbromid (Spiriva(R) Respimat, ATC: R03BB04) | Pharmaceutical products | - | Nov 28, 2026 | Sep 25, 2024 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-11 - Hepatitis-B-Immunglobulin (ATC-Code J06BB04) | Pharmaceutical products | - | Oct 29, 2026 | Sep 22, 2024 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-08 - Fluticason/Vilanterol (Wirkstoffkombination) | Pharmaceutical products | - | Sep 30, 2026 | Jul 30, 2024 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-07 - Dapagliflozin | Pharmaceutical products | - | Aug 29, 2026 | Jul 19, 2024 | Active |
| Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-06 - Aclidiniumbromid/Formoterol (Wirkstoffkombination) Framework | Pharmaceutical products | - | Aug 29, 2026 | Jul 15, 2024 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-04 - Follitropin alfa Framework | Pharmaceutical products | - | Jul 29, 2026 | Jun 21, 2024 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-06 - Peginterferon beta-1a Framework | Pharmaceutical products | - | Jul 29, 2026 | Jun 20, 2024 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-08 - Darbepoetin alfa Framework | Pharmaceutical products | - | Jul 29, 2026 | Jun 19, 2024 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-05 - Ustekinumab Framework | Pharmaceutical products | - | Jul 29, 2026 | Jun 17, 2024 | Active |
| Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2024-07 - Epoetin zeta Framework | Pharmaceutical products | - | Jul 29, 2026 | Jun 17, 2024 | Active |
| Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-03 - Everolimus (ATC: L04AH02; TAB) Framework | Pharmaceutical products | - | Oct 29, 2026 | Feb 15, 2024 | Active |